Get Started

TELO

NASD Telomir Pharmaceuticals, Inc.
Nov 5, 2026 · 12:10 AM ET EOD Market Closed

$0.8750 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.8750, $0.0550 below the day’s high of $0.9300

YTD change
-34.21%
vs 20-day SMA
-14.79%
vs 200-day SMA
-28.17%

Price ranges

Previous day
$0.9100 $0.9500
open $0.9271 close $0.9100
-$0.0171 (-1.84%)
Today
$0.8550 $0.9300
open $0.9100 now $0.8750
-$0.0350 (-3.85%)
Past week
$0.7905 $1.0500
from $1.0200 now $0.8750
-$0.1450 (-14.22%)
Past month
$0.7905 $1.2000
from $1.2000 now $0.8750
-$0.3250 (-27.08%)
This year
$0.7905 $1.5800
from $1.3300 now $0.8750
-$0.4550 (-34.21%)

Price & Performance

-0.45 (-33.71%) / 6M

$0.8314$1.04$1.25$1.46May 4Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 95.8% away from all-time highs of $20.7200
  • TELO is down 34% since the beginning of the year
  • TELO is down 38% over the past 12 months
  • TELO is down 27% over the past 1 month
  • 2% of all TELO investors are betting against TELO

TELO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -37.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.03
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $50.3M
Beta -0.30

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$5.2M
Debt$136.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $64.4M

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,417.99 +0.61%
JNJ Johnson & Johnson $276.32 +3.81%
ABBV AbbVie, Inc. $294.83 +3.09%
MRK Merck & Co., Inc. $150.36 +3.93%
RHHBY Roche Holding Ltd Sponsored ADR $60.94 +2.97%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.